WallStreetZenWallStreetZen

NASDAQ: VERO
Venus Concept Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for VERO

Based on 1 analyst offering 12 month price targets for Venus Concept Inc.
Min Forecast
$5.50+1,191.08%
Avg Forecast
$5.50+1,191.08%
Max Forecast
$5.50+1,191.08%

Should I buy or sell VERO stock?

Based on 1 analyst offering ratings for Venus Concept Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VERO stock forecasts and price targets.

VERO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BTIG
Top 8%
93
Strong BuyMaintains$5.50+1,191.08%2022-06-24

1 of 1

Forecast return on equity

Is VERO forecast to generate an efficient return?
Company
-29.38%
Industry
19.64%
Market
108.79%
VERO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VERO forecast to generate an efficient return on assets?
Company
-4.93%
Industry
10.86%
VERO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VERO earnings per share forecast

What is VERO's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.47
Avg 2 year Forecast
-$0.20
Avg 3 year Forecast
-$0.10

VERO revenue forecast

What is VERO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$111.7M+0.75%
Avg 2 year Forecast
$125.0M+12.75%
Avg 3 year Forecast
$137.8M+24.29%
VERO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VERO revenue growth forecast

How is VERO forecast to perform vs Medical Devices companies and vs the US market?
Company
6.11%
Industry
4.48%
Market
8.22%
VERO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VERO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VERO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
VERO$0.43$5.50+1,191.08%Strong Buy
DCTH$3.27$19.50+496.33%Strong Buy
SSKN$0.84$4.30+411.90%Strong Buy
NMTC$1.89N/AN/AHold
AFIB$0.87$2.00+129.36%Hold

Venus Concept Stock Forecast FAQ

Is Venus Concept Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VERO) stock is to Strong Buy VERO stock.

Out of 1 analyst, 1 (100%) are recommending VERO as a Strong Buy, 0 (0%) are recommending VERO as a Buy, 0 (0%) are recommending VERO as a Hold, 0 (0%) are recommending VERO as a Sell, and 0 (0%) are recommending VERO as a Strong Sell.

If you're new to stock investing, here's how to buy Venus Concept stock.

What is VERO's earnings growth forecast for 2022-2024?

(NASDAQ: VERO) Venus Concept's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 26.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.27%.

Venus Concept's earnings in 2022 is -$33,309,000.On average, 2 Wall Street analysts forecast VERO's earnings for 2022 to be -$30,765,999, with the lowest VERO earnings forecast at -$31,420,595, and the highest VERO earnings forecast at -$30,111,404. On average, 2 Wall Street analysts forecast VERO's earnings for 2023 to be -$13,091,915, with the lowest VERO earnings forecast at -$13,746,510, and the highest VERO earnings forecast at -$13,091,915.

In 2024, VERO is forecast to generate -$6,545,957 in earnings, with the lowest earnings forecast at -$12,437,319 and the highest earnings forecast at -$654,596.

What is VERO's revenue growth forecast for 2022-2024?

(NASDAQ: VERO) Venus Concept's forecast annual revenue growth rate of 6.11% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.22%.

Venus Concept's revenue in 2022 is $110,869,000.On average, 1 Wall Street analysts forecast VERO's revenue for 2022 to be $7,311,834,304, with the lowest VERO revenue forecast at $7,311,834,304, and the highest VERO revenue forecast at $7,311,834,304. On average, 1 Wall Street analysts forecast VERO's revenue for 2023 to be $8,182,446,625, with the lowest VERO revenue forecast at $8,182,446,625, and the highest VERO revenue forecast at $8,182,446,625.

In 2024, VERO is forecast to generate $9,020,329,159 in revenue, with the lowest revenue forecast at $9,020,329,159 and the highest revenue forecast at $9,020,329,159.

What is VERO's forecast return on assets (ROA) for 2022-2024?

(NASDAQ: VERO) forecast ROA is -4.93%, which is lower than the forecast US Medical Devices industry average of 10.86%.

What is VERO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VERO price target, the average VERO price target is $5.50, with the highest VERO stock price forecast at $5.50 and the lowest VERO stock price forecast at $5.50.

The Wall Street analyst predicted that Venus Concept's share price could reach $5.50 by Jun 24, 2023. The average Venus Concept stock price prediction forecasts a potential upside of 1,191.08% from the current VERO share price of $0.43.

What is VERO's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: VERO) Venus Concept's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that VERO's EPS will be -$0.47 for 2022, with the lowest EPS forecast at -$0.48, and the highest EPS forecast at -$0.46. On average, analysts forecast that VERO's EPS will be -$0.20 for 2023, with the lowest EPS forecast at -$0.21, and the highest EPS forecast at -$0.20. In 2024, VERO's EPS is forecast to hit -$0.10 (min: -$0.19, max: -$0.01).

What is VERO's forecast return on equity (ROE) for 2022-2024?

(NASDAQ: VERO) forecast ROE is -29.38%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.